Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Cellectis S.A.
Cellectis S.A.
Columbia University
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Arbeitsgemeinschaft medikamentoese Tumortherapie
Weill Medical College of Cornell University
University of California, San Diego
Mayo Clinic
Baylor College of Medicine
M.D. Anderson Cancer Center
Columbia University
National Institutes of Health Clinical Center (CC)
German CLL Study Group
Baylor College of Medicine
Ontario Clinical Oncology Group (OCOG)
Sanofi
Sanofi
National Cancer Institute (NCI)
Assistance Publique - Hôpitaux de Paris
Baylor College of Medicine